Lushchekina SV - Search Results

1

Role of Protein Dimeric Interface in Allosteric Inhibition of N-Acetyl-Aspartate Hydrolysis by Human Aspartoacylase.

Kots ED, Lushchekina SV, Varfolomeev SD, Nemukhin AV. Kots ED, et al. Among authors: lushchekina sv. J Chem Inf Model. 2017 Aug 28;57(8):1999-2008. doi: 10.1021/acs.jcim.7b00133. Epub 2017 Aug 4. J Chem Inf Model. 2017. PMID: 28737906

2

Correlation between the substrate structure and the rate of acetylcholinesterase hydrolysis modeled with the combined quantum mechanical/molecular mechanical studies.

Lushchekina SV, Nemukhin AV, Morozov DI, Varfolomeev SD. Lushchekina SV, et al. Chem Biol Interact. 2010 Sep 6;187(1-3):59-63. doi: 10.1016/j.cbi.2010.04.005. Epub 2010 Apr 14. Chem Biol Interact. 2010. PMID: 20398640

3

On quantum mechanical--molecular mechanical (QM/MM) approaches to model hydrolysis of acetylcholine by acetylcholinesterase.

Nemukhin AV, Grigorenko BL, Morozov DI, Kochetov MS, Lushchekina SV, Varfolomeev SD. Nemukhin AV, et al. Among authors: lushchekina sv. Chem Biol Interact. 2013 Mar 25;203(1):51-6. doi: 10.1016/j.cbi.2012.08.027. Epub 2012 Sep 13. Chem Biol Interact. 2013. PMID: 22982775

4

Molecular modeling evidence for His438 flip in the mechanism of butyrylcholinesterase hysteretic behavior.

Lushchekina SV, Nemukhin AV, Varfolomeev SD, Masson P. Lushchekina SV, et al. J Mol Neurosci. 2014 Mar;52(3):434-45. doi: 10.1007/s12031-013-0178-2. Epub 2013 Dec 6. J Mol Neurosci. 2014. PMID: 24310732

5

Molecular modeling of mechanism of action of anti-myasthenia gravis slow-binding inhibitor of acetylcholinesterase.

Lushchekina S, Kots E, Kharlamova A, Petrov K, Masson P. Lushchekina S, et al. Int J Risk Saf Med. 2015;27 Suppl 1:S74-5. doi: 10.3233/JRS-150696. Int J Risk Saf Med. 2015. PMID: 26639721

6

Slow-binding inhibition of acetylcholinesterase by an alkylammonium derivative of 6-methyluracil: mechanism and possible advantages for myasthenia gravis treatment.

Kharlamova AD, Lushchekina SV, Petrov KA, Kots ED, Nachon F, Villard-Wandhammer M, Zueva IV, Krejci E, Reznik VS, Zobov VV, Nikolsky EE, Masson P. Kharlamova AD, et al. Among authors: lushchekina sv. Biochem J. 2016 May 1;473(9):1225-36. doi: 10.1042/BCJ20160084. Epub 2016 Feb 29. Biochem J. 2016. PMID: 26929400

7

Understanding the non-catalytic behavior of human butyrylcholinesterase silent variants: Comparison of wild-type enzyme, catalytically active Ala328Cys mutant, and silent Ala328Asp variant.

Lushchekina S, Nemukhin A, Varfolomeev S, Masson P. Lushchekina S, et al. Chem Biol Interact. 2016 Nov 25;259(Pt B):223-232. doi: 10.1016/j.cbi.2016.04.007. Epub 2016 Apr 7. Chem Biol Interact. 2016. PMID: 27062896

8

Modeling the Complete Catalytic Cycle of Aspartoacylase.

Kots ED, Khrenova MG, Lushchekina SV, Varfolomeev SD, Grigorenko BL, Nemukhin AV. Kots ED, et al. Among authors: lushchekina sv. J Phys Chem B. 2016 May 12;120(18):4221-31. doi: 10.1021/acs.jpcb.6b02542. Epub 2016 Apr 29. J Phys Chem B. 2016. PMID: 27089954

9

Three Faces of N-Acetylaspartate: Activator, Substrate, and Inhibitor of Human Aspartoacylase.

Khrenova MG, Kots ED, Varfolomeev SD, Lushchekina SV, Nemukhin AV. Khrenova MG, et al. Among authors: lushchekina sv. J Phys Chem B. 2017 Oct 12;121(40):9389-9397. doi: 10.1021/acs.jpcb.7b08759. Epub 2017 Sep 27. J Phys Chem B. 2017. PMID: 28903559

10

Optimization of Cholinesterase-Based Catalytic Bioscavengers Against Organophosphorus Agents.

Lushchekina SV, Schopfer LM, Grigorenko BL, Nemukhin AV, Varfolomeev SD, Lockridge O, Masson P. Lushchekina SV, et al. Front Pharmacol. 2018 Mar 13;9:211. doi: 10.3389/fphar.2018.00211. eCollection 2018. Front Pharmacol. 2018. PMID: 29593539 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page